Quelles complications peuvent survenir avec la thérapie aversive ?
Des complications émotionnelles comme l'anxiété ou la dépression peuvent survenir.
ComplicationsAnxiété
#2
La thérapie aversive peut-elle aggraver certains symptômes ?
Oui, elle peut aggraver des symptômes chez certains patients sensibles ou vulnérables.
Aggravation des symptômesVulnérabilité
#3
Quels sont les effets à long terme de cette thérapie ?
Les effets à long terme peuvent inclure une réduction des comportements, mais aussi des effets négatifs.
Effets à long termeComportement
#4
Comment gérer les complications éventuelles ?
Un suivi régulier et un ajustement des techniques peuvent aider à gérer les complications.
SuiviGestion des complications
#5
Les complications sont-elles fréquentes ?
Elles ne sont pas systématiques, mais peuvent survenir selon la sensibilité du patient.
Fréquence des complicationsSensibilité
Facteurs de risque
5
#1
Quels facteurs augmentent le risque de comportements indésirables ?
Des antécédents familiaux de troubles mentaux et un environnement stressant peuvent augmenter le risque.
Facteurs de risqueEnvironnement
#2
Le stress est-il un facteur de risque ?
Oui, le stress chronique peut contribuer au développement de comportements indésirables.
StressComportement
#3
Les troubles mentaux prédisposent-ils à la thérapie aversive ?
Oui, certains troubles mentaux peuvent rendre la thérapie aversive plus nécessaire.
Troubles mentauxThérapie aversive
#4
L'isolement social est-il un facteur de risque ?
Oui, l'isolement social peut exacerber les comportements indésirables et les addictions.
Isolement socialAddiction
#5
Les antécédents de traumatismes influencent-ils le risque ?
Oui, les traumatismes passés peuvent augmenter la probabilité de comportements problématiques.
TraumatismesComportement
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Thérapie aversive : Questions médicales les plus fréquentes",
"headline": "Thérapie aversive : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Thérapie aversive : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-24",
"dateModified": "2025-02-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Thérapie aversive"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Thérapie comportementale",
"url": "https://questionsmedicales.fr/mesh/D001521",
"about": {
"@type": "MedicalCondition",
"name": "Thérapie comportementale",
"code": {
"@type": "MedicalCode",
"code": "D001521",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "F04.754.137"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Thérapie aversive",
"alternateName": "Aversive Therapy",
"code": {
"@type": "MedicalCode",
"code": "D001348",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Morten Moshagen",
"url": "https://questionsmedicales.fr/author/Morten%20Moshagen",
"affiliation": {
"@type": "Organization",
"name": "Ulm University, Albert-Einstein-Allee 47, 89081, Ulm, Germany."
}
},
{
"@type": "Person",
"name": "Benjamin E Hilbig",
"url": "https://questionsmedicales.fr/author/Benjamin%20E%20Hilbig",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychology, RPTU Kaiserslautern-Landau, Fortstr. 7, 76829, Landau, Germany."
}
},
{
"@type": "Person",
"name": "Erich Seifritz",
"url": "https://questionsmedicales.fr/author/Erich%20Seifritz",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland."
}
},
{
"@type": "Person",
"name": "Adrien T Stanley",
"url": "https://questionsmedicales.fr/author/Adrien%20T%20Stanley",
"affiliation": {
"@type": "Organization",
"name": "Departments of Biology and Psychiatry, Columbia University, New York, NY, United States."
}
},
{
"@type": "Person",
"name": "David Sulzer",
"url": "https://questionsmedicales.fr/author/David%20Sulzer",
"affiliation": {
"@type": "Organization",
"name": "Departments of Psychiatry, Neurology, and Pharmacology, Columbia University Medical Center, New York, NY, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Impact of Receipt of Information on Prostate-Specific Antigen Testing on Screening with the Prostate-Specific Antigen Test.",
"datePublished": "2023-01-18",
"url": "https://questionsmedicales.fr/article/36652189",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s13187-023-02264-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostate-Specific Antigen Screening in Transgender Patients.",
"datePublished": "2022-11-04",
"url": "https://questionsmedicales.fr/article/36344317",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.eururo.2022.09.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.",
"datePublished": "2022-07-21",
"url": "https://questionsmedicales.fr/article/35860909",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/pros.24414"
}
},
{
"@type": "ScholarlyArticle",
"name": "Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.",
"datePublished": "2022-09-24",
"url": "https://questionsmedicales.fr/article/36253300",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clgc.2022.09.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Opportunities for prostate-specific membrane antigen hybrid imaging in prostate cancer].",
"datePublished": "2023-09-13",
"url": "https://questionsmedicales.fr/article/37702749",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00120-023-02189-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Disciplines et activités comportementales",
"item": "https://questionsmedicales.fr/mesh/D004191"
},
{
"@type": "ListItem",
"position": 3,
"name": "Psychothérapie",
"item": "https://questionsmedicales.fr/mesh/D011613"
},
{
"@type": "ListItem",
"position": 4,
"name": "Thérapie comportementale",
"item": "https://questionsmedicales.fr/mesh/D001521"
},
{
"@type": "ListItem",
"position": 5,
"name": "Thérapie aversive",
"item": "https://questionsmedicales.fr/mesh/D001348"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Thérapie aversive - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Thérapie aversive",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Thérapie aversive",
"description": "Comment diagnostiquer un besoin de thérapie aversive ?\nQuels tests sont utilisés pour évaluer les comportements ?\nQui peut prescrire une thérapie aversive ?\nQuels critères sont utilisés pour le diagnostic ?\nLa thérapie aversive est-elle adaptée à tous ?",
"url": "https://questionsmedicales.fr/mesh/D001348?mesh_terms=Prostate-Specific+Antigen#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Thérapie aversive",
"description": "Quels symptômes indiquent un besoin de thérapie aversive ?\nComment se manifestent les comportements indésirables ?\nLes symptômes varient-ils selon les individus ?\nQuels effets émotionnels peuvent résulter de ces comportements ?\nLes symptômes physiques sont-ils liés à la thérapie aversive ?",
"url": "https://questionsmedicales.fr/mesh/D001348?mesh_terms=Prostate-Specific+Antigen#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Thérapie aversive",
"description": "Comment prévenir les comportements indésirables ?\nLes interventions précoces sont-elles efficaces ?\nQuel rôle joue le soutien social dans la prévention ?\nLes programmes éducatifs sont-ils utiles ?\nComment la thérapie préventive est-elle mise en œuvre ?",
"url": "https://questionsmedicales.fr/mesh/D001348?mesh_terms=Prostate-Specific+Antigen#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Thérapie aversive",
"description": "Comment fonctionne la thérapie aversive ?\nQuels types de stimuli sont utilisés ?\nLa thérapie aversive est-elle efficace ?\nCombien de séances sont généralement nécessaires ?\nY a-t-il des alternatives à la thérapie aversive ?",
"url": "https://questionsmedicales.fr/mesh/D001348?mesh_terms=Prostate-Specific+Antigen#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Thérapie aversive",
"description": "Quelles complications peuvent survenir avec la thérapie aversive ?\nLa thérapie aversive peut-elle aggraver certains symptômes ?\nQuels sont les effets à long terme de cette thérapie ?\nComment gérer les complications éventuelles ?\nLes complications sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D001348?mesh_terms=Prostate-Specific+Antigen#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Thérapie aversive",
"description": "Quels facteurs augmentent le risque de comportements indésirables ?\nLe stress est-il un facteur de risque ?\nLes troubles mentaux prédisposent-ils à la thérapie aversive ?\nL'isolement social est-il un facteur de risque ?\nLes antécédents de traumatismes influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D001348?mesh_terms=Prostate-Specific+Antigen#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un besoin de thérapie aversive ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un professionnel évalue les comportements problématiques et leur impact sur la vie quotidienne."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les comportements ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des questionnaires et des entretiens cliniques sont souvent utilisés pour l'évaluation."
}
},
{
"@type": "Question",
"name": "Qui peut prescrire une thérapie aversive ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un psychologue ou un psychiatre qualifié peut prescrire cette thérapie après évaluation."
}
},
{
"@type": "Question",
"name": "Quels critères sont utilisés pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent la fréquence et l'intensité des comportements indésirables."
}
},
{
"@type": "Question",
"name": "La thérapie aversive est-elle adaptée à tous ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elle n'est pas recommandée pour tous les patients, surtout ceux avec des troubles graves."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un besoin de thérapie aversive ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des comportements compulsifs ou des addictions peuvent nécessiter cette thérapie."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les comportements indésirables ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent se manifester par des actions répétitives nuisibles ou des dépendances."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'individu et de la situation."
}
},
{
"@type": "Question",
"name": "Quels effets émotionnels peuvent résulter de ces comportements ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les individus peuvent ressentir de la honte, de l'anxiété ou de la dépression."
}
},
{
"@type": "Question",
"name": "Les symptômes physiques sont-ils liés à la thérapie aversive ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes physiques peuvent apparaître en raison du stress lié aux comportements."
}
},
{
"@type": "Question",
"name": "Comment prévenir les comportements indésirables ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation et la sensibilisation aux conséquences des comportements peuvent aider à prévenir."
}
},
{
"@type": "Question",
"name": "Les interventions précoces sont-elles efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des interventions précoces peuvent réduire le développement de comportements problématiques."
}
},
{
"@type": "Question",
"name": "Quel rôle joue le soutien social dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un bon soutien social peut aider à réduire les comportements indésirables en offrant des alternatives."
}
},
{
"@type": "Question",
"name": "Les programmes éducatifs sont-ils utiles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent sensibiliser aux risques et aux conséquences des comportements indésirables."
}
},
{
"@type": "Question",
"name": "Comment la thérapie préventive est-elle mise en œuvre ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut inclure des séances de groupe ou des ateliers sur la gestion des comportements."
}
},
{
"@type": "Question",
"name": "Comment fonctionne la thérapie aversive ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle associe un comportement indésirable à un stimulus désagréable pour réduire ce comportement."
}
},
{
"@type": "Question",
"name": "Quels types de stimuli sont utilisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des stimuli tels que des sons désagréables ou des sensations physiques peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "La thérapie aversive est-elle efficace ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut être efficace pour certains comportements, mais les résultats varient selon les individus."
}
},
{
"@type": "Question",
"name": "Combien de séances sont généralement nécessaires ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le nombre de séances varie, mais plusieurs semaines sont souvent nécessaires pour des résultats."
}
},
{
"@type": "Question",
"name": "Y a-t-il des alternatives à la thérapie aversive ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des approches comme la thérapie cognitivo-comportementale peuvent être envisagées."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la thérapie aversive ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications émotionnelles comme l'anxiété ou la dépression peuvent survenir."
}
},
{
"@type": "Question",
"name": "La thérapie aversive peut-elle aggraver certains symptômes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aggraver des symptômes chez certains patients sensibles ou vulnérables."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme de cette thérapie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets à long terme peuvent inclure une réduction des comportements, mais aussi des effets négatifs."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications éventuelles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier et un ajustement des techniques peuvent aider à gérer les complications."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles ne sont pas systématiques, mais peuvent survenir selon la sensibilité du patient."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de comportements indésirables ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux de troubles mentaux et un environnement stressant peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer au développement de comportements indésirables."
}
},
{
"@type": "Question",
"name": "Les troubles mentaux prédisposent-ils à la thérapie aversive ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles mentaux peuvent rendre la thérapie aversive plus nécessaire."
}
},
{
"@type": "Question",
"name": "L'isolement social est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'isolement social peut exacerber les comportements indésirables et les addictions."
}
},
{
"@type": "Question",
"name": "Les antécédents de traumatismes influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traumatismes passés peuvent augmenter la probabilité de comportements problématiques."
}
}
]
}
]
}
Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Youzheng Street 23, Nangang District, Harbin, 150001, Heilongjiang Province, People's Republic of China.
Institute of Brain Science, Harbin Medical University, Harbin, People's Republic of China.
There is controversy on prostate cancer screening with the prostate-specific antigen (PSA) test in the USA, and as a result, there has been an increased push for physicians to have a thorough discussi...
Approximately 0.4-1.3% of the worldwide population is transgender. Although the exact prevalence is unknown, there is an increase in open identification as transgender. Among transgender women (TW), t...
To assess our current understanding of CaP incidence and prostate-specific antigen (PSA) screening in TW....
We performed a nonsystematic narrative review of all PubMed publications through June 2022 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. Given ...
There is no consensus regarding PSA screening in TW from any of the major societies, and TW are largely absent from guidelines. Case report data suggest that TW with CaP may have more aggressive disea...
We are in the infancy of our understanding of PSA screening in TW. Important avenues for future research include understanding the risks/benefits of PSA screening in TW, how best to mitigate potential...
We examined patterns of prostate cancer screening for transgender women. Little is known about prostate cancer incidence or screening in this population. Additional research is needed to establish gui...
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is increasingly incorporated in the therapeutic algorithm of patients with metastatic castration-resistant prostate cancer ...
In this bicentric analysis, we included 184 mCRPC patients treated with...
A total of 114/184 patients (62.0%) showed any PSA decline (PSA response >50%, 55/184 [29.9%]). For individuals exhibiting a PSA decline >50%, OS of 19 months was significantly longer relative to nonr...
In mCRPC patients scheduled for RLT, early biochemical response was tightly linked to prolonged survival, irrespective of the magnitude of PSA decline. As such, even in patients with PSA decrease of l...
In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals....
This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ...
It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high...
As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...
Prostate-specific membrane antigen (PSMA) hybrid imaging is a promising new technique gaining importance in the field of prostate cancer (PCa) diagnosis and treatment planning. By combining PSMA radio...
Prostate-specific antigen (PSA) screening for prostate cancer is controversial but may be associated with benefit for certain high-risk groups....
To evaluate associations of county-level PSA screening prevalence with prostate cancer outcomes, as well as variation by sociodemographic and clinical factors....
This cohort study used data from cancer registries based in 8 US states on Hispanic, non-Hispanic Black, and non-Hispanic White men aged 40 to 99 years who received a diagnosis of prostate cancer betw...
County-level PSA screening prevalence was estimated using the Behavior Risk Factor Surveillance System survey data from 2004, 2006, 2008, 2010, and 2012 and weighted by population characteristics....
Multivariable logistic, Cox proportional hazards regression, and competing risks models were fit to estimate adjusted odds ratios (AOR) and adjusted hazard ratios (AHR) for associations of county-leve...
Of 814 987 men with prostate cancer, the mean (SD) age was 67.3 (9.8) years, 7.8% were Hispanic, 12.2% were non-Hispanic Black, and 80.0% were non-Hispanic White; 17.0% had advanced disease. There wer...
This population-based cohort study of men with prostate cancer suggests that higher county-level prevalence of PSA screening was associated with lower odds of advanced disease, all-cause mortality, an...
The incidence rate of prostate cancer (PCa) has continued to rise in Korea. This study aimed to construct and evaluate a 5-year PCa risk prediction model using a cohort with PSA < 10 ng/mL by incorpor...
The PCa risk prediction model including PSA levels and individual risk factors was constructed using a cohort of 69,319 participants from the Kangbuk Samsung Health Study. 201 registered PCa incidence...
The risk prediction model included age, smoking status, alcohol consumption, family history of PCa, past medical history of dyslipidemia, cholesterol levels, and PSA level. Especially, an elevated PSA...
Our risk prediction model was effective in predicting PCa in a population according to PSA levels. When PSA levels are inconclusive, an assessment of both PSA and specific individual risk factors (e.g...
For metastatic hormone naïve prostate cancer patients, androgen deprivation therapy (ADT) with escalation therapy including docetaxel and/or androgen targeting drugs is the standard therapy. However, ...
Prostate biopsies from 92 patients with metastatic hormone naïve PC (PSA > 80 ng/mL or clinical metastases) were immunohistochemically evaluated for PSA and Ki67. Gene expression analysis was performe...
The immunohistochemical score for PSA was the strongest prognostic factor for progression-free and overall survival after ADT. Consequently, the ratio between Ki67 and PSA displayed a stronger prognos...
PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The re...
To investigate the value of serum free prostate-specific antigen density (fPSAD) in the diagnosis of prostate cancer (PCa)....
The data of 558 patients who underwent transrectal ultrasound-guided prostate biopsy were retrospectively analyzed. According to the pathological results, the patients were divided into a PCa group an...
tPSA, PSAD, (f/t)/PSAD, and fPSAD had high accuracy in predicting PCa with AUC values of 0.820, 0.900, 0.846, and 0.867. fPSAD showed lower diagnostic sensitivity but significantly higher specificity ...
With the optimal cutoff value of 0.062, fPSAD has a higher diagnostic value for PCa than tPSA, f/tPSA, (f/t)/PSAD, and PSAD, and can well predict the risk of PCa, significantly improve the clinical di...
Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over the age of 50 years. An association between the prostate specific antigen (PSA), International Pro...
To determine the correlation between the PSA, IPSS and PV in men of African descent....
This was a cross sectional analysis involving 92 patients diagnosed as having symptomatic BPH at the Ho Teaching Hospital....
The data were collected using standardised questionnaires. The IPSS determined urinary symptom severity. The PV was determined using a transabdominal ultrasound machine. Serum PSA was retrieved from t...
The mean PV was 61.04 cm3 ± 21.95 cm3, the mean PSA was 4.21 ng/mL ± 3.85 ng/mL, and mean IPSS of 21.59 ± 3.78. The Pearson's correlation between PV and PSA was 0.283 (p = 0.01), between PV and IPSS w...
This study showed that serum PSA has a positive correlation with PV. However, IPSS had no significant association with PSA or PV in patients with BPH.Contribution: This study provides insights into th...
